Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) are complex diseases with undiscovered genetic factors. We successfully discovered a deleterious variant in VSIG10L segregating in a large family. This is the first such reported gene for susceptibility to BE and EAC. VSIG10L appears to function in adhesion and differentiation/maturation of stratified squamous epithelium. Further clues for a genetic basis comes from our admixture mapping study, which has identified two specific chromosomal regions associated with excess European ancestry in African Americans. The BETRNet focus of Project 1 is thus to identify the genetic basis of racial disparity in the prevalence of BE and EAC. A second BETRNet focus of Project 1 is to create a genetically engineered mouse model based on VSIG10L to understand the transformation from squamous epithelium to metaplastic Barrett's epithelium. This project will now build on these discoveries by: 1) Using dense SNP genotyping, NextGen sequencing, and ATAC-seq to identify racially disparate genetic variants that explain racial differences in prevalence of BE and EAC; 2) Using genetically engineered VSIG10L knockout and VSIG10L S631G variant carrying mice to understand how VSIG10L contributes to the normal squamous epithelium ? esophagitis ? BE metaplasia ? dysplasia ? cancer progression; The significance of Project 1 is first to translate the clinical observation of racial disparity in BE and EAC into the laboratory to identify a causative genetic basis. Furthermore, the project will build on our successful discovery of the first familial susceptibility genetic variant by understanding how this gene functions in metaplastic transformation of Barrett's epithelium.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54CA163060-06
Application #
9276255
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2011-09-26
Project End
2022-04-30
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
6
Fiscal Year
2017
Total Cost
$253,699
Indirect Cost
$94,889
Name
Case Western Reserve University
Department
Type
Domestic Higher Education
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Berger, Nathan A; Scacheri, Peter C (2018) Targeting Epigenetics to Prevent Obesity Promoted Cancers. Cancer Prev Res (Phila) 11:125-128
Codipilly, Don Chamil; Chandar, Apoorva Krishna; Singh, Siddharth et al. (2018) The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. Gastroenterology 154:2068-2086.e5
Evans, Daniel R; Venkitachalam, Srividya; Revoredo, Leslie et al. (2018) Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer. Hum Mutat 39:1092-1101
Chan, M Q; Blum, A E; Chandar, A K et al. (2018) Association of sporadic and familial Barrett's esophagus with breast cancer. Dis Esophagus 31:
Yu, Ming; Maden, Sean K; Stachler, Matthew et al. (2018) Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut :
Berger, Nathan A (2018) New light on the pancreatic cyst conundrum. Transl Cancer Res 7:S545-S548
Berger, Nathan A (2018) Young Adult Cancer: Influence of the Obesity Pandemic. Obesity (Silver Spring) 26:641-650
Moinova, Helen R; LaFramboise, Thomas; Lutterbaugh, James D et al. (2018) Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. Sci Transl Med 10:
Stachler, Matthew D; Camarda, Nicholas D; Deitrick, Christopher et al. (2018) Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology 155:156-167
Venkitachalam, Srividya; Guda, Kishore (2017) Altered glycosyltransferases in colorectal cancer. Expert Rev Gastroenterol Hepatol 11:5-7

Showing the most recent 10 out of 69 publications